GRAIL, Inc. (GRAL)
Detects multiple cancers early through a blood test for people over 50.
$64.42-0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+96.5%
The outlook
GRAL trades near its 50- and 200-day moving averages, sitting in the lower half of its 52-week range. Analysts lean Buy with an average target about 9% above the current price, though the overall StockGlow score remains neutral. The stock is essentially flat today.
What’s behind the score
Analyst consensusBuy — 2.1 avg of 8 analysts
Price trendBelow its 50- & 200-day averages
52-week range39% of the way from its 52-week low to high
Price targetAvg target +9% vs current price
Analyst price target
~12-month · 8 analysts$70.13average target+8.9% vs now
Now $64.42
Low $56.00High $88.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.76B
52-wk high
$118.84
52-wk low
$29.95
50-day avg
$66.31
200-day avg
$74.31
Trailing P/E
—